The clinical trial GaReCo has been initiated in two additional sites: Lübeck and Wolfsburg. This study examines whether vaccination with Gardasil® prevents the recurrence of genital warts caused by HPV types 6 and 11 after standard therapy. It is planned to enroll 200 patients into the trial. Recruitment will now be performed in 9 trial sites within Germany.
For further information regarding the trial please visit the EU Clinical Trials Register.
vom 19.04.2016
Clinical Trial GaReCo: additional trial sites initiated
